Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.11 - $10.54
Previous CloseN/A
Volume368.97K
Average Volume (3M)299.55K
Market Cap
$53.98M
Enterprise Value$3.91M
Total Cash (Recent Filing)$22.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.75
Next Earnings
Nov 05, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding19,486,230
10 Day Avg. Volume251,444
30 Day Avg. Volume299,551
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$12.33Price Target Upside345.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease, which is seen as a significant step forward.
Regulatory StrategyAnalysts view the alignment with the FDA on a pivotal trial with both 6-month and 18-month endpoints as a positive development for buntanetap's potential approval.
Stock ValuationThe product's mechanism and early Alzheimer's disease data generated so far remain very intriguing, and the stock is viewed as significantly undervalued over the longer term.
Bears Say
Financing ChallengesThe 12-month price target is reduced to $12 from the prior $30 per share to reflect the impact of the most recent equity financing, future potential equity issuances, and the exercise of warrants.
Market ConditionsBroad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.11 and its highest was $10.54 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $53.98M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 05, 2025 which is in 83 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.082.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.33.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 19,486,230 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (345.13% Upside)
$12.33 (345.13% Upside)
Blogger Sentiment
Neutral
ANVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.80%
12-Months-Change
Fundamentals
Return on Equity
-280.78%
Trailing 12-Months
Asset Growth
242.20%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.33
▲(345.13% Upside)
Technical Analysis
Generation Bio
―
PolyPid
―
BioAtla
―
Coeptis Therapeutics Holdings
―
MiNK Therapeutics
―
Ownership Overview
14.34% Insiders
3.86% Mutual Funds
1.86% Other Institutional Investors
76.40% Public Companies and
Individual Investors